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Available online 25 May 2016Immunogenicity and safety of different adjuvants combined with a model antigen (HBsAg) were compared.
Healthy HBV-naïve adults were randomized to receive HBs adjuvanted with alum or Adjuvant Systems AS01B,
AS01E, AS03A or AS04 at Days 0 and 30. Different frequencies of HBs-speciﬁc CD4+ T cells 14 days post dose
2 but similar polyfunctionality proﬁles were induced by the different adjuvants with frequencies signiﬁcantly
higher in the AS01B and AS01E groups than in the other groups. Antibody concentrations 30 days post-dose 2
were signiﬁcantly higher in AS01B, AS01E and AS03A than in other groups. Limited correlations were observed
between HBs-speciﬁc CD4+ T cell and antibody responses. Injection site pain was the most common solicited
local symptom and was more frequent in AS groups than in alum group. Different adjuvants formulated with
the same antigen induced different adaptive immune responses and reactogenicity patterns in healthy naïve
adults.
The results summary for this study (GSK study number 112115 – NCT# NCT00805389) is available on the GSK
Clinical Study Register and can be accessed at www.gsk-clinicalstudyregister.com.
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Adjuvants are included in vaccines with the aim of accelerating,
prolonging or enhancing the intrinsic immunogenicity of antigens [1].
Aluminum salts were ﬁrst used as adjuvants in the 1920′s [2] and are
still widely utilized in human vaccines. However, aluminum salts pre-
dominantly promote antibody responses [3,4] that reach protective levels
only aftermultiple vaccine doses. In addition, aluminum-adjuvanted vac-
cines are ofmore limited usewhen strong T cell responses are required to
protect against complex pathogens, chronic infections, or in populations
such as the elderly or immunocompromised [5–8]. These limitations
have led to the development of variety of new adjuvants based on oil-
in-water (o/w) emulsions, saponins and Toll-like receptor agonists.
These substances, used alone or in combination, are essentialthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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development [9].
AS01 is an Adjuvant System family containing the TLR4 agonist 3-O-
desacyl-4′-monophosphoryl lipid A (MPL) and QS-21 (Quillaja
saponariaMolina, fraction 21) formulated with liposomes. It has been
developed to potentiate T cell responses against challenging pathogens
where classical approaches have proven less effective [10,11]. This is ex-
empliﬁed by the RTS,S/AS01 candidate vaccine which targets Plasmodi-
um falciparum and has been shown to elicit 31% and 50% protective
efﬁcacy against clinical malaria in infants and children, respectively
[12,13], and by the candidate subunit glycoprotein E varicella zoster
HZ/su vaccine inducing N95% protection in older adults [14]. AS03A, an
Adjuvant System containing α-Tocopherol and squalene in an o/w
emulsion promotes the rapid production of cross-reactive antibodies
and allows for antigen-sparing as demonstrated with a pre-pandemic
H5N1 candidate vaccine [15,16] and with the licensed H1N1 inﬂuenza
vaccine [17]. AS04, an Adjuvant System containing MPL adsorbed on
Al salt enhances antibody and T cell responses and is included in the li-
censed human papillomavirus vaccineHPV-16/18 for prevention of cer-
vical cancer [18,19] and in a hepatitis B virus (HBV) vaccine for use in
patients with renal insufﬁciency [20].
These Adjuvant Systems have been shown to induce enhanced anti-
body and T cell responses in numerous clinical studies targeting a variety
of pathogens and somehave been compared in clinical trials (e.g., in com-
bination with the candidate malaria RTS, S antigen and the candidate
Herpes Zoster antigen), providing valuable information on differential re-
sponses in the respective settings [21–23]. Additionally, as a precursor to
the current study, Adjuvant Systems containing MPL and QS-21 were
compared in a clinical trial using a well-characterizedmodel antigen (re-
combinant hepatitis B virus surface antigen [HBsAg]) [24,25]. However,
AS03 and AS04, which are already used in licensed products, have not
previously been compared with AS01. To gain further insight into the in-
duced immune proﬁle and to assist in their rational inclusion in future
vaccines, a study has been set up to compare the immunogenicity and
safety of AS01, AS03, AS04 and alum in a head-to-head clinical trial.
These adjuvants have been combined with HBsAg, and were evaluated
in healthy, young HBV-naïve adults to minimize confounding factors.
Herewe ﬁrst report on the antibody, T and B cell responses to HBsAg
aswell as the reactogenicity and safety proﬁles of the different formula-
tions up to Day 60. Additional analyses deciphering innate and adaptive
immune responses will be the subject of future reports.
2. Material and methods
2.1. Study design and participants
This was an observer-blind, randomized, controlled trial
(ClinicalTrials.gov identiﬁer: NCT00805389) conducted at 14 study cen-
ters (4 in Belgium and 10 in Germany) from December 2008 to July
2011. The protocol was approved by all institutional Ethics Committees
and was conducted in accordance with the Declaration of Helsinki and
GoodClinical Practice guidelines.Written informed consentwas obtain-
ed from each participant before trial participation. Eligible participants
were healthy men and women aged 18–45 years. Exclusion criteria
were: previous vaccination against HBV; positive for anti-HBs antibod-
ies, anti-HBc antibodies, HBsAg, antibodies against hepatitis C virus and/
or HIV; previous administration of MPL or QS-21 (Q. saponariaMolina,
fraction 21) (Licensed byGSK fromAntigenics Inc., awholly owned sub-
sidiary of Agenus Inc., a Delaware, USA corporation); administration of
any other investigational or non-registered product (drug or vaccine)
within the last 30 days or planned use during the study period; admin-
istration or planned administration of a vaccine not foreseen by the
study protocol within the last 30 dayswith the exception of the inﬂuen-
za vaccine which could be administered N21 days preceding or follow-
ing each primary vaccine dose and N7 days preceding or following the
booster dose; chronic administration of immunosuppressants or otherimmune-modifying drugs within the last six months; administration
of immunoglobulins and/or any blood products within the last three
months, any conﬁrmed or suspected immunosuppressive or immuno-
deﬁcient condition, history of allergic disease or reactions likely to be
exacerbated by vaccine components; other conditions that the investi-
gator judged may interfere with study ﬁndings.
A target of 710 eligible participants (142 per group) were to be ran-
domized (1:1:1:1:1) to receive 20 μg HBsAg adjuvanted with alum or
one of four GSK proprietary Adjuvants Systems (AS01B, AS01E [contain-
ing half the quantity of MPL and QS-21 as in AS01B], AS03A or AS04) at
Days 0 and 30. The vaccine formulations are shown in Fig. 1. Vaccine
doses were administered by intramuscular injection into the deltoid
muscle of the non-dominant arm. The primary endpoint (HBs-speciﬁc
T cells) was assessed for all participants. Secondary and exploratory
endpoints were evaluated in a sub-cohort of participants (375 planned;
75 per group) (Supplementary Fig. 1). Allocation of participants to the
sub-cohort was based on HLA type, determined at screening, in order
to allow analyses of HBsAg-derived peptide speciﬁc T cell responses
(see Supplementary Material).
2.2. Treatment allocation and blinding
Participants were allocated a unique treatment number using a cen-
tralized randomization system on internet. The randomization algo-
rithm used a minimization procedure accounting for country of
recruitment, pre-selected HLA type and gender. When 375 participants
had been allocated to the sub-cohort, HLA typing was stopped and the
remaining participantswere then randomized only according to gender
and country. The study was conducted in an observer-blinded manner.
Full blinding could not be done due to the different appearance and
preparation of the vaccines. Vaccine preparation and administration
were performed by authorized medical personnel who did not partici-
pate in any of the clinical evaluations. Study participants and those re-
sponsible for the evaluation of study endpoints were unaware of
group allocation.
2.3. Immunological evaluation
For analyses describedhere, blood sampleswere collected onDays 0,
14, 30, 37, 44 and 60 (Fig. 1). All assayswere done at central laboratories
(ImmuneHealth, Gosselies, Belgium for cell-mediated immunity assays;
GSK Vaccines, Rixensart, Belgium formeasurement of anti-HBs antibod-
ies) as described below.
2.3.1. HBs-speciﬁc CD4+ and CD8+ T cells
HBs-speciﬁc CD4+ and CD8+ T cells weremeasured using frozen pe-
ripheral blood mononuclear cells (PBMCs) by the intracellular cytokine
staining assay using adaptations of previously described methods [24,
26,27]. Brieﬂy, PBMCs were stimulated in vitro with a pool of peptides
(15-mers overlapping by 11 amino acids and covering the entire
HBsAg sequence; at 0.5 μg/mL/peptide; Eurogentec S.A.) and medium
(negative control) for 2 h in the presence of anti-CD28 (CD28.2) and
anti-CD49d (9F10) antibodies (from BD Biosciences). Cytokine secre-
tion inhibitor (Golgi Plug, BD Pharmingen containing Brefeldin A) was
added 2 h after start of culture (stimulation with peptides) and the cul-
ture was further incubated overnight. After in vitro stimulation, PBMC
were stained with extracellular markers, CD4 V450 (SK3) and CD8
APC Cy7 (SK1) (BDBiosciences) and permeabilized in Cytoﬁx/Cytoperm
solution (BD Pharmingen). The cells were then stained with the follow-
ing antibodies: CD40L PE (TRAP1), IL-2 FITC (MQ1-17H12), TNF-α PE-
Cy7 (Mab11), IFN-γ Alexa 700 (4S·B3) all from BD Biosciences; IL-13
APC (JES10-5A2) from Biolegend, IL-17 PerCp Cy 5.5 (eBio64DEC17)
from eBiosciences Inc. and CD3 Paciﬁc Orange (UCHT1) from Caltag
Medsystems Ltd. Finally, cells were acquired on a LSRII ﬂow cytometer
(BD Biosciences) and analyzed using FlowJo version 9 software (Tree
Star Inc., Ashland, OR, USA).
Fig. 1. Composition of each vaccine formulation and schedule of assessments to Day 60. The upper part of the ﬁgure shows the composition of each vaccine formulation. The study
schematic in the lower part of the ﬁgure shows the times of vaccine administration for each group (Days 0 and 30) and the timing of collection of blood samples for the
immunological endpoints described in the current analysis to Day 60. *also contains squalene in an oil-in-water emulsion. †Al(OH)3 for Alum group and AlPO4 for AS04 group.
‡Participants in the sub-cohort for evaluation of secondary and exploratory endpoints were followed to Day 390; subjects not in the sub-cohort were followed to Day 360.
18 G. Leroux-Roels et al. / Clinical Immunology 169 (2016) 16–272.3.2. Anti-HBs antibodies
Anti-HBs antibodies were measured using a commercial
chemiluminometric immunoassay (CLIA) (Centaur XP™ anti-HBs
assay, Siemens Healthcare, Germany). Seropositivity and seropro-
tection were deﬁned as anti-HBs concentrations ≥ 6.2 mIU/mL and
≥10 mIU/mL, respectively.
2.3.3. HBs-speciﬁc memory B cells
Frequencies of HBs-speciﬁc memory B cells were quantiﬁed by
enzyme-linked immunosorbent spot (ELISPOT) assay [28]. Brieﬂy,
memory B cells were induced to differentiate into plasma cells follow-
ing in vitro incubation of PBMC with unmethylated DNA (CpG2006 at
3 μg/mL, Eurogentec, Belgium) for 5 days. In vitro-generated plasma
cells were then incubated in culture plates previously coated with
5 μg/mL of recombinant HBsAg or with 1 μg/mL of anti-human immu-
noglobulin G (IgG) (Goat anti-human Afﬁnipure, Jackson Laboratories)
to enumerate speciﬁc antibody or IgG secreting plasma cells, respective-
ly. The antibody/antigen spots formed were detected by a conventional
immunoenzymatic procedure, as described previously [28]. Data are
expressed as number of HBs-speciﬁc IgG-producing memory B cells
per million of IgG-producing memory B cells.
2.4. Safety evaluation
Solicited local symptoms of pain, redness and swelling and general
symptoms of fatigue, fever (oral temperature ≥ 37.5 °C), gastrointestinal
(nausea, vomiting, diarrhea or abdominal pain), headache, malaise and
myalgia were recorded for 14 days after each vaccine dose. Unsolicited
adverse events (AEs) were recorded for 31 days after each vaccine
dose. The intensity of symptoms was graded on a 3-point scale. Grade3 symptoms were deﬁned as redness or swelling N 50 mm in diameter,
oral temperature N 39.5 °C, and, for other symptoms, as preventing nor-
mal activity. Solicited local symptomswere considered to be causally re-
lated to vaccination. The investigator used clinical judgement to
determine whether there was a reasonable possibility that the other
solicited or unsolicited AEmight have been caused by the study vaccine.
The occurrence of serious adverse events (SAEs) and AEs of special in-
terest including potential immune-mediated diseases (pIMDs)were re-
ported throughout the entire study period. pIMDswere followed due to
the concern of acquiring a vaccine-induced disease of possible autoim-
mune etiology in susceptible individuals after vaccination with a prod-
uct containing an adjuvant [29].
2.5. Objectives and endpoints
The pre-speciﬁed primary objective was to compare the frequency of
HBs-speciﬁc CD4+ T cells expressing at least two immune markers
among, CD40L, IL-2, TNF-α, IFN-γ, IL-13 and IL-17, between groups
using PBMCs at Day 44. Secondary objectives reported here include
between-group comparison of anti-HBs antibody concentrations at Day
60, descriptive summaries of the kinetics of HBs-speciﬁc T cell, antibody
and memory B cell responses up to Day 60, relationships between adap-
tive responses, and reactogenicity and safety up to Day 60. Post hoc anal-
yses on the frequency of HBs-speciﬁc CD4+ T cells expressing at least
CD40L and, on the polyfunctionality of CD4+ T cells, in those participants
who were deemed to be CD4+ T cell responders, were conducted (see
statistical analysis section). Post hoc analyses also included the between-
group comparison of anti-HBs antibody concentrations at Day 44.
Innate immune response analysis, as well as results on adaptive im-
mune response quality (including persistence and boostability) will be
reported elsewhere.
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In previous clinical trials, AS01 induced a potent cellular response re-
gardless of the antigen or the population [11]. Therefore, the higher
dose AS01 group (AS01B) was selected as the primary comparator and
sample size was estimated on the basis of comparisons between other
adjuvant groups and this group. Assuming a within group standard de-
viation (SD) of 1.144 on the log10 scale, it was estimated that 135
evaluable participants per group (total of 675) would be required to
show at least a 3-fold difference between the AS01B group and any of
the other groups in terms of the frequency of HBs-speciﬁc CD4+ T
cells at Day 44 using Dunnett's method with a power of at least 88%
and a global type I error of 5%. It was assumed that approximately 5%
of participants would be excluded from the per protocol analysis, there-
fore, the target enrolment was 710 participants.
Immunogenicity analyses were based on the according to protocol
(ATP) cohort for assessment of adaptive immunogenicity,which included
all evaluable participants (i.e., those meeting all eligibility criteria, com-
plying with the procedures deﬁned in the protocol, with no elimination
criteria during the study) for whom data concerning immunogenicity
endpoint measures were available. The geometric mean of T and B cells'
frequency (GMFs) and the geometric mean of the antibodies' concentra-
tion (GMCs) were calculated. Comparisons of GMFs for HBs-speciﬁc
CD4+ T cells and GMCs for anti-HBs antibodies between the AS01B
group and other groups used Dunnett's method via a one-way analysis
of variance model. Geometric mean ratios and associated adjusted 95%
conﬁdence intervals were calculated. Additional pairwise comparisons
between groups used Bonferroni's adjustment method to control the
overall type I error. To evaluate relationships between adaptive immune
responses at Days 30, 44 and 60, scatter plots were constructed and post
hoc Pearson's correlation coefﬁcients were calculated. In the primary
analysis, data were expressed as number of HBs-speciﬁc CD4+ T cells ex-
pressing at least two immune markers per million CD4+ T cells after
subtracting backgroundvalues. Theprimary analysis showedbackground
noise at baseline characterized predominately by combinations of cyto-
kines excluding CD40L. Since previous studies have shown that respond-
er cells can be characterized by their expression of CD40L [30–32], post
hoc analyses on the frequencies of HBs-speciﬁc CD4+ T cells expressing
at least CD40L were performed which allowed reduction of the back-
ground noise due to non-speciﬁc CD4+ T cell responses.
For all participants in the ATP cohort, we compared the frequency of
CD4+ T cells expressing at least CD40L at Day 14 and Day 44 between
groups using the same methods as those used for the analysis of the
pre-speciﬁed endpoints (no adjustment for multiple time points per-
formed). For responders, deﬁned as participants with a frequency of
CD4+ T cells expressing at least CD40L above the pre-vaccination thresh-
old (=95th percentile of the frequency calculated on pooled groups at
pre-vaccination), we also summarized the frequencies of HBs-speciﬁc
CD4+ T cells expressing any combination of CD40L and the three other
markers (IL-2, TNF-α and IFN-γ) at Day 44 using descriptive statistics
(bar charts and pie charts). We excluded IL-13 and IL-17 from this analy-
sis of polyfunctionality since post hoc exploratory analyses showed that
there was no difference in the frequency of CD4+ T cells expressing IL-
13 and IL-17 between pre- and post-vaccination (Supplementary Fig. 2).
Finally, we calculated a polyfunctionality index [33] for each responder
to enumerate the proportion of cells expressing different numbers of im-
mune markers as a single value:
Polyfunctionality index ¼ F1  14þ F2 
2
4
þ F3  34þ F4
where F1 represent the frequencies (%) of cells producing CD40L alone
and F2, F3 and F4 represent the frequencies (%) of cells expressing
CD40L in combination with 1, 2 or 3 markers, respectively, with
F1 + F2 + F3 + F4 = 100%. Polyfunctionality indices were summarized
for each group using descriptive statistics.Descriptive summaries of demographic and safety data were based
on the total vaccinated cohort, which included all participants for
whom at least one vaccine administration was documented.
Statistical analyses were done using SAS version 9.2 (SAS Institute,
Cary, NC, USA) and ProcStatXact 8.1 (Cytel Inc., Cambridge, MA, USA).3. Results
3.1. Study population
The composition of each vaccine as well as the schedule for admin-
istration and assessments are given in Fig. 1. A total of 713 participants
were randomized and received at least one vaccine dose and 691 partic-
ipants completed the study to Day 60, with the number of participants
who withdrew from the study being similar among groups (Supple-
mentary Fig. 1). A total of 623 participants received two vaccine doses.
Temporary suspension of dosing was undertaken due to two cases of
autoimmune hepatitis in a separate study evaluating an AS03A-
adjuvanted vaccine. The two cases were found to be in existence before
vaccination and thus unrelated. Dosing was resumed after 4 weeks, but
for 74 participants the second dose was not administered because it
would have been out of schedule. These participants were not included
in the ATP cohort (for full details see SupplementaryMaterial) andwere
evenly distributed among groups. The ATP cohort for assessment of
adaptive immunogenicity included 599 (84%) participants. The major
reason for exclusion from the ATP cohort was that vaccine doses were
not administered according to the planned schedule (80 [11%] partici-
pants, of which 74 received only one vaccine dose due to the temporary
suspension of dosing). A total of 373 participants were enrolled in the
sub-cohort for evaluation of antibody and memory B cell responses,
and of these, 293 (79%) were included in the ATP cohort. The groups
were well matched in terms of age, race and gender (Table 1).3.2. Impact of adjuvants on the magnitude of CD4+ T cell responses
The magnitude of the HBs-speciﬁc CD4+ T cell responses was mea-
sured as the frequency of cells expressing at least two markers among
six, in response to ex vivo stimulation with peptides spanning the HBs
antigen, as done previously [24]. An additional post hoc analysis based
on the frequency of cells expressing at least CD40L upon antigen stimu-
lation was also conducted. In the AS01B, AS01E and AS03A groups, the
GMFs of HBs-speciﬁc CD4+ T cells initially peaked 14 days after the
ﬁrst vaccine dose and then declined over the ensuing twoweeks. Levels
increased again after the second vaccine dose and a second higher peak
was observed at Day 44, both for cells expressing at least CD40L and for
cells expressing at least two markers. In the alum group, GMFs of CD4+
T cells increased more steadily over the observation period (Fig. 2A and
Supplementary Fig. 3).
The AS01B- and AS01E-based formulations induced the highest
GMFs of HBs-speciﬁc CD4+ T cells and no statistically signiﬁcant differ-
ences were observed between these two groups. For cells expressing at
least CD40L, GMFs were statistically higher for both the AS01B and
AS01E groups compared with the AS03A group at Day 44 (1.83 [1.28,
2.62]- and 1.69 [1.18, 2.43]-fold higher, respectively), which in turn
was higher than the AS04 group (2.48 [1.74, 3.53]-fold) and the alum
group (3.23 [2.26, 4.61]-fold). No statistically signiﬁcant difference in
the frequencies of CD4+ T cells was observed between the AS04 and
alum groups. Similar results were observedwhen CD4+ T cell responses
were measured as GMFs of cells expressing at least two of six markers
(Supplementary Fig. 3 and Supplementary Table 1). For cells expressing
at least CD40L, no differences could be observed at Day 14, with the
GMF of AS01B 0.86 (0.63, 1.16)-fold lower than AS03A and the GMF of
AS01E 0.92 (0.66, 1.29)-fold lower than AS03A at this earlier time
point (Supplementary Table 1).
Table 1
Demographic characteristics.
Group Total
Cohort Characteristic AS01B AS01E AS03A AS04 Alum
TVC Number of participants 143 142 141 145 142 713
Age (years) at ﬁrst vaccination, mean (SD) 34.7 (6.94) 33.7 (7.28) 32.9 (7.58) 33.5 (7.41) 32.9 (7.50) 33.6 (7.35)
Female, n (%) 66 (46.2) 66 (46.5) 64 (45.4) 66 (45.5) 65 (45.8) 327 (45.9)
Race, n (%)
African Heritage/African American 0 (0.0) 0 (0.0) 2 (1.4) 0 (0.0) 0 (0.0) 2 (0.3)
Asian Heritage 1 (0.7) 1 (0.7) 0 (0.0) 1 (0.7) 3 (2.1) 6 (0.8)
White Heritage 140 (97.9) 139 (97.9) 138 (97.9) 144 (99.3) 139 (97.9) 700 (98.2)
Other 2 (1.4) 2 (1.4) 1 (0.7) 0 (0.0) 0 (0.0) 5 (0.7)
ATP Number of participants 121 120 118 124 116 599
Age (years) at ﬁrst vaccination, mean (SD) 34.9 (7.02) 34.0 (7.23) 33.1 (7.63) 33.4 (7.17) 33.4 (7.10) 33.8 (7.23)
Female, n (%) 59 (48.8) 55 (45.8) 51 (43.2) 54 (43.5) 51 (44.0) 270 (45.1)
Race, n (%)
African Heritage/African American 0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.2)
Asian Heritage 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.8) 3 (2.6) 5 (0.8)
White Heritage 119 (98.3) 119 (99.2) 116 (98.3) 123 (99.2) 113 (97.4) 590 (98.5)
Other 2 (1.7) 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 3 (0.5)
ATP, according-to-protocol cohort for adaptive immunogenicity; n (%), number (percentage) of participants in a given category; SD, standard deviation; TVC, total vaccinated cohort.
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(data not shown) as was the case in other studies using recombinant
protein antigens [24,34].3.3. Impact of adjuvants on the magnitude of B cell responses and
antibodies
Signiﬁcant differences were observed in themagnitude and kinetics
of antibody and memory B cell responses between the groups.Fig. 2. Effect of different adjuvants on the kinetics of the adaptive immune responses for the A
CD40L; (B) the concentration of anti-HBs antibodies; and (C) the frequency of HBs-speciﬁ
participants receiving vaccine doses on Day 0 and Day 30 consisting of HBsAg 20 μg/dose, a
(dark blue). Geometric mean values (geomean) and 95% conﬁdence intervals are shown.In the AS01B, AS01E and AS03A groups, anti-HBs antibody titers in-
creased after each of the two vaccine doses (Fig. 2B) and reached statis-
tically signiﬁcant higher GMCs at Day 44 and Day 60 comparedwith the
AS04 group, which in turnwas statistically signiﬁcantly higher than the
alum group. A statistically signiﬁcant difference was observed between
GMCs in the AS01B group vs. the AS03A group at Day 44 (2.17 [1.13,
4.18]-fold higher) but not at Day 60 (Supplementary Table 2). No statis-
tically signiﬁcant differences in anti-HBs GMCs were observed between
the AS01E and AS03A groups at Day 44 or Day 60 (Supplementary
Table 2). According to the measurements performed at Day 44 andTP cohort. Plots show (A) the frequency of HBs-speciﬁc CD4+ T cells expressing at least
c memory B cells (on the sub-cohort for antibody and memory B cell responses) for
djuvanted with alum (black), AS04 (red), AS03A (green), AS01E (light blue) and AS01B
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AS01 and AS03A groups (observed at Day 44 for 87.5% and 80.7% of par-
ticipants, respectively) as compared with the AS04 group (53%) and the
alum group (26%) (Supplementary Table 3).
At Day 60, antibodies levels of ≥10mIU/mLwere reached for 100% of
participants in theAS01B, AS01E andAS03A groups, 93.2% of participants
in the AS04 group and 58.2% of participants in the alum group.
As observed for antibodies, the frequencies of HBs-speciﬁc memory
B cell responses increased after each vaccine dose in the AS01B, AS01E,
AS03A groups and after the second vaccine dose in the AS04 and alum
groups, with no or low increase observed post dose 1. In the four Adju-
vant Systems groups, the B cell responses tended to peak between Days
30 and 44 (Fig. 2C). In the alumgroup, the B cell response tended to take
longer to reach the maximum observed value compared to the other
groups. Similar to antibodies, observed GMFs of HBs-speciﬁc memory
B cells were higher in the AS01B, AS01E, AS03A groups than in the
AS04 and alum groups (GMFs for HBs-speciﬁc memory B cells at Day
44 were 3729, 4042, 1436, 28 and 14 per 106 cells, respectively, but no
statistical comparisons were performed) (Supplementary Table 4).
3.4. Relationship between T cell and antibody responses
Weexploredwhether antigen-speciﬁc T cellsmeasured in the blood,
monitored via expression of CD40L or cytokines upon restimulation
were correlated to antibody levels. Correlations between the frequen-
cies of HBs-speciﬁc CD4+ T cells and anti-HBs antibody titers were gen-
erally low (Fig. 3). At Day 44 and 60, the highest correlations were
observed in the AS03A group (Pearson's correlation coefﬁcient, R =
0.6 and 0.5 respectively). Observed correlations were lower in the
AS01E group (R ≤ 0.4) and were even very low in the AS01B group
(R ≤ 0.14), as shown by themore vertical position of the predictive ellip-
se for this group. Correlations in the AS04 and alum groups should be
considered with caution considering the low numbers of responders
for the antibody and CD4+ T cell responses.
3.5. Polyfunctionality of CD4+ T cell responses to adjuvants
Adjuvants could potentially induce qualitative, in addition to quanti-
tative, differences in the CD4+ T cell responses [1], because they differ-
entially activate innate immunity.
As a ﬁrst approach to test this hypothesis, the polyfunctionality of
HBs-speciﬁc CD4+ T cells was analyzed. The analysis was focused on
CD4+ T cells producing at least CD40L and was restricted to participants
showing a response to the formulations. As shown in Fig. 4, the proposed
intracellular cytokine staining assay showed that theHBs-speciﬁc CD4+T
cells induced by the ﬁve vaccine formulations had similar patterns of
polyfunctionality. Similar percentages of cells producing 1, 2 or 3markers
among CD40L+ cells were detected in the different groups (Fig. 4A). The
predominant populations were cells producing CD40L only or in combi-
nation with either IL-2, or IL-2 and TNF-α. Low frequencies of cells pro-
ducing IFN-γ were only detected in the AS01B and AS01E groups
(Fig. 4A and B). In order to quantify the polyfunctionality of HBS-
speciﬁc CD4+ T cells, an index was calculated in which polyfunctional
cells have a higher weight than pauci-functional cells [33]. As shown in
Fig. 4C, the polyfunctionality indexes of HBs-speciﬁc CD4+ T cells were
similar in the ﬁve groups.
3.6. Safety and reactogenicity
The differences in immunogenicity of the ﬁve vaccine formulations
were associated with differences in their reactogenicity proﬁles, with
an apparent lower reactogenicity in the alum group than in the four Ad-
juvant System groups (Fig. 5 and Supplementary Table 5). A tendency
towards a higher frequency of solicited symptoms was observed for
the AS01B-adjuvanted vaccine as compared to the other adjuvanted for-
mulations. In all groups, the symptoms were transient with the highestfrequency occurring within the ﬁrst two days after dosing and preva-
lence declined rapidly thereafter (Supplementary Figs. 4 and 5). Only
a small proportion of participants had symptoms beyond Day 6.
A larger proportion of participants in the Adjuvant System vaccine
groups had pain at the injection site, local redness or local swelling com-
pared to the alum group (Fig. 5 and Supplementary Table 5). Grade 3
local symptoms were most common in the AS01B group whereas no
participants in the alum group experienced grade 3 local symptoms.
Themost frequently solicited general symptomswere fatigue, headache
and myalgia and these symptoms were more frequent in the AS01B
group than other groups (Fig. 5 and Supplementary Table 5). Grade 3
general symptoms occurred at low frequencies and were generally
comparable across groups.
In general, reactogenicity (solicited local and general symptoms) did
not increase after the second vaccine dose, except in the AS01B group,
for which systemic, but not local, reactogenicity tended to be higher
after dose 2 (Fig. 5 and Supplementary Table 5).
Unsolicited AEs and SAEs up to Day 60 are described in the Supple-
mentary Material and Supplementary Table 6. The prevalence and
type of unsolicited AEswas similar in each group (~50% of participants).
None of the reported AEs leading towithdrawal (3 participants) or SAEs
(15 events for 12 participants)were considered to be related to vaccina-
tion by the investigator.
4. Discussion
Here, we describe cellular and humoral immune responses, as well
as reactogenicity and safety parameters, following vaccination with
two doses of study vaccines up to Day 60. The current direct comparison
should provide data assisting adjuvant selection decisions in future vac-
cine development and establishes a framework in which the value of
new adjuvants can be evaluated.
Several conclusions can be drawn. First, the different HBsAg vaccine
formulations induced markedly different adaptive immune reactions,
whichwas expected given the current clinical experiencewith the adju-
vant systems. In addition, the use of Adjuvant Systems allows a faster
onset of the immune response as compared to alum, with the highest
response obtained after two weeks post immunization. However, de-
spite being quantitatively different, CD4+ T cells induced by the differ-
ent vaccine formulations displayed comparable functionality proﬁles,
dominated by expression of IL-2 and CD40L. Second, no obvious corre-
lations between antibody titers and CD4+ T cell frequencies were ob-
served although there was a trend towards less variability in antibody
titers with increasing CD4+ T cell frequencies. Third, reactogenicity pro-
ﬁles differed between the different formulations with the interesting
observation that for the HBsAg/AS01B vaccine, reactogenicity after the
second dose seemed to be higher than after the ﬁrst dose.
4.1. Cellular immune responses
In terms of CD4+ T cell and B cell responses, the highest frequencies
were observed following vaccinationwith theAS01B or AS01E adjuvanted
vaccines. Immune responses appeared to show a dichotomy, with AS01E,
AS01B andAS03A inducing relatively stronger responses on onehand, and
AS04 and alum inducing relatively weaker responses on the other hand.
Immune responses were already detected after the ﬁrst dose for the
AS01 and AS03A adjuvanted vaccines with no clear differentiation be-
tween AS01 and AS03A groups in this population of naïve adults. Re-
sponses rose sharply after two vaccine doses and at subsequent
sampling times. It is of interest that the AS04-adjuvanted vaccine induced
lower frequencies of CD4+ T cells as compared to AS01. AS04 also con-
tainsMPL but adsorbed on an aluminum salt in an aqueous solution rath-
er than combinedwithQS-21 in a liposome formulation as in AS01. These
results are consistentwithmouse studies indicating that theMPL andQS-
21 components of AS01 act synergistically rather than additively, to stim-
ulate induction of CD4+ T cell responses [35]. This is not seen whenMPL
Fig. 3. Relationship between anti-HBs antibody concentrations and frequency of HBs-speciﬁc CD4+ T cells expressing at least CD40L at Days 30, 44 and 60 for the ATP cohort. Scatter plots
showing relationship at Day 30, Day 44 and Day 60 between the anti-HBs antibody concentrations (x-axis) versus the frequency of HBs-speciﬁc CD4+ T cells expressing at least CD40L as
measured by intracellular cytokine staining following re-stimulation of peripheral bloodmononuclear cells (y-axis) for participants in the ATP cohort for adaptive immunogenicity (sub-
cohort only). Each dot represents an individual participant and the ellipse represents the 95% prediction. The reference lines on each plot represent the cut-offs deﬁning responders for
CD4+ T-cells (frequency of HBs-speciﬁc CD4+ T-cells expressing at least CD40L N 418 per 106 cells [=95th percentile of the frequency calculated on pooled groups at pre-
vaccination]) and for antibodies (anti-HBs concentration N 6.2 mIU/mL [=pre-deﬁned seropositivity concentration]). The Pearson's correlation coefﬁcient (R) is shown in the upper
left hand corner. On each scatter plot, the bottom right hand corner contains the percentage of individuals within each of the quadrants deﬁned by the reference lines.
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potential added value of combiningdifferent active components in anAd-
juvant System to support the increased induction of CD4+T cell and B cell
responses. Induction of robust CD4+ T cell responses was not limited to
the AS01 formulations. The AS03A-based formulation also induced high
frequencies of HBs-speciﬁc CD4+ T cells, albeit lower than in the AS01
groups. Formulation with AS03 also boosted antibody responses.
Although the vaccine formulations induced quantitatively different
T and B cell responses, the functional proﬁles of HBsAg-speciﬁc CD4+T cells were strikingly similar in the ﬁve study groups, as measured by
the intracellular cytokine staining assay. The dominant functional
markers produced were CD40L, IL-2 and, to a lesser extent TNF-α,
whereas relatively small proportions of antigen-speciﬁc cells produced
IFN-γ. These observations are surprising given the different nature of
the adjuvants included in the formulations and their reported effect
on T cell differentiation in animalmodels [36–38]. Thereby, the different
effect of adjuvants on innate immunity may not directly translate into a
different quality of T cell responses in humans but rather result in an
Fig. 4. Polyfunctionality of the CD4+ T cell responses induced by different adjuvants for participants deﬁned as “responders” in theATP cohort. Pie charts (A) and bar graphs (B) of cytokine
co-expression proﬁles of HBsAg-speciﬁc CD4+CD40L+ T cells at 2weeks post-dose II (Day 44) in the ﬁve study groups for participants in the ATP cohort for adaptive immunogenicity who
were deﬁned as “responders” (deﬁned as participants with frequency of CD4+ T cells expressing at least CD40L above threshold= 95th percentile of the frequency calculated on pooled
groups at pre-vaccination). Results were expressed as the percentage in pie charts (A) or as the absolute cell numbers in bar graph (B) of the total CD4+CD40L+ T cells expressing 1, 2 or 3
cytokines (IL-2, TNF-α or IFN-γ). Individual results and median of polyfunctionality index (C) calculated on CD4+ T cells expressing at least CD40L, alone or with an additional 1, 2, or 3
markers.
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Fig. 5.Radar plots of solicited local and general symptoms after each dose for the total vaccinated cohort. Each spoke on the radar plot shows one of the solicited local or general symptoms
(clockwise from top: PA, pain; RE, redness; SW, swelling; FE, fever; FA, fatigue; HE, headache;MY,myalgia;MA,malaise; GI, gastrointestinal). The outer end of each spoke represents 100%
of participants, and the inner end of each spoke represents 0%of participants. The green dot-dashed line shows thepercentage of participantswith any grade of the symptom, the blue solid
line shows the percentage of participants with grade 1 of the symptom and the red dashed line shows the percentage of participants with grade 2 of the symptom.
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ber of parametersmeasured. Amore extensive analysis of secreted cyto-
kines or gene expression proﬁles may reveal differences and this
analysis is ongoing. Indeed, distinct transcriptional signatures were de-
tected in murine T cells that appeared to be similar by ﬂow cytometric
analysis [39]. In addition, only peripheral T cells were measured,
which may not reﬂect what is ongoing in the lymph node or germinal
centers.
No antigen-speciﬁc CD8+ T cell responses were detected in any of
the adjuvant groups, conﬁrming earlier data from clinical studies. In
preclinical studies, however, CD8+ T cell responses could be detected
[11,40–42]. In mice, spleen cells [40] and PBMCs [41] were examined
and in rhesus macaques [41,42] PBMCs were re-stimulated with pep-
tides in vitro before cytotoxic T lymphocyte (CTL) analyses. Moreover,
in humans, CTL analyses have been demonstrated with adjuvanted
HBsAg vaccination after in vitro expansion of the cells [43]. Therefore,
comparisons need to bemade with great care and with methodological
differences in mind.
4.2. Antibody responses
At Day 60, one month after the second vaccine dose, all participants
in the AS01B, AS01E, and AS03A groups had reached anti-HBs levels of
≥10 mIU/mL, compared with 93% in the AS04 group and 58% in the
alum group. Signiﬁcantly higher antibody responses and numerically
higher rates of antibody levels ≥ 10 mIU/mL were detected in the
AS04 group as compared to the alum group, despite the induction of
similar frequencies of HBsAg-speciﬁc CD4+ T cell and memory B cells.
This capacity of AS04 to boost antibody responses is further illustrated
by its capacity to improve antibody responses to HBsAg in patients
with end stage renal disease [44,45] and to HPV-16/18 antigens in
adolescents and adults [46]. The relatively low rates of antibody
levels ≥ 10 mIU/mL observed in the alum group are consistent with
the need of three doses to achieve seroprotection in most HBsAg-
naïve individuals. CD4+ T cell frequencies and antibody titers correlated
poorly up to Day 60 despite displaying similar hierarchies between the
vaccine formulations. Further analyses are needed to evaluate whether
the CD4+ T cell frequencies and qualities can predict the persistence of
the humoral response beyond Day 60.
4.3. Reactogenicity
The differential magnitudes of T and B cell responses to the vac-
cine formulations were associated with differences in reactogenicity.
Pain was the most common solicited AE reported by participants re-
ceiving AS-adjuvanted vaccines and this occurred at higher
frequency and intensity as compared to alum. An increase in local
reactogenicity may reﬂect the local activation of the innate immune
system by Adjuvant Systems, as described in mice and in vitro on
human cells [36–38]. Local reactogenicity was more pronounced in
the AS01B group compared to the AS01E group (containing half the
amount of MPL and QS-21). Interestingly, systemic reactogenicity
was higher after the second vaccine dose as compared to the ﬁrst
for the AS01B group, while local reactogenicity remained unchanged.
This was not observed for any of the other groups. It will be of
interest to better understand the mechanism behind this dose-
dependency of systemic reactogenicity. The AS01E and AS01B groups
did not differ signiﬁcantly in terms of CD4+ T cell and antibody re-
sponses, indicating that comparable immune responses can be in-
duced with reduced reactogenicity, at least in the current study
population, i.e. HBsAg-naïve, younger adults.
5. Conclusions
Although the present study allows for an objective and informative
comparison of adjuvants, the results cannot simply be extrapolated toother populations and antigen/adjuvant combinations. Population dif-
ferences in terms of age (e.g., children vs. elderly), immune status (im-
munocompromised vs. healthy), physiological status (pregnancy),
factors pertaining to the host or ethnic origin (e.g., HLA haplotype or
other genetic host determinants) and/or pre-existing immunity
(i.e., naive vs. primed) have to be taken into account when selecting ad-
juvants for any vaccine candidate.
In conclusion, this study shows that different adjuvants have a pro-
found impact on the kinetics and the magnitude of T and B cell re-
sponses to a given protein vaccine in humans. Further analyses from
this study should determine the impact of adjuvants on the quality of
these responses and on their relationship with innate immune re-
sponses and with reactogenicity. Taken together, these analyses will
provide essential information for the selection of adjuvants in the devel-
opment of efﬁcacious and safe vaccines.
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